But with delayed gastric emptying, that gas has nowhere to go
Using some naive assumptions here (that the average weight loss required for the average obese persons BMI to be below 30 and thus not categorized as obese, assuming x% of obese people take the drug and all experience the average reduction in body weight), we can see a picture emerge that shows the potential to disrupt a trend thats been forming for the past 50 years
Review the mechanism, human research, dosage context, and an honest look at the limits
Slow wound healing and irritation of the skin
Use in type 1 diabetes: Evidence and clinical rationale While randomised controlled trials, such as SURPASS-T1D-1 (clinicaltrials.gov identifier NCT06914895) and SURPASS-T1D-2 (NCT06962280), are ongoing, growing real-world evidence suggests that tirzepatide may serve as an effective adjunct to insulin in people with obesity and type 1 diabetes
Also keep in mind that out-of-pocket costs can vary depending on insurance coverage